Evidence map›Paper›PMID 41000700›Full record

ArticlebioRxiv : the preprint server for biology2025

Metabolomic, Lipidomic, and Enterohormone Changes in the Progression from MASLD to MASH.

Jaclyn A Rivas, Alexandria C Murphy, Praveena Prasad, Siem S Goitom, Aaron S Romero, Crystal Madera Enriquez, Brianna B Maes, Prithvi R Akepati, Marcus A Garcia, Fredine T Lauer and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jaclyn A RivasDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Alexandria C MurphyDepartment of Biochemistry and Molecular Biology, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA 16802, USA.
Praveena PrasadDepartment of Biochemistry and Molecular Biology, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA 16802, USA.
Siem S GoitomDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Aaron S RomeroDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Crystal Madera EnriquezDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Brianna B MaesDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Prithvi R AkepatiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Marcus A GarciaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Fredine T LauerDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Rama R GullapalliDepartment of Pathology, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.ORCID 0000-0003-4441-1402
Kristen M GonzalesDivision of Endocrinology and Metabolism, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Jessica M GrossClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Jing PuDepartment of Molecular Genetics and Microbiology, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Shuguang LengDepartment of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Julie G InDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.ORCID 0000-0001-7075-3444
Melanie R McReynoldsDepartment of Biochemistry and Molecular Biology, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA 16802, USA.
Eliseo F CastilloDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.ORCID 0000-0002-5083-560X

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Unfolded Protein Response and Autophagy in T Helper Cell Effector FunctionP20GM121176 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Samuel Joseph Endicott · 2017 to 2026
$24.9M
Initiative to Maximize Student Diversity at the University of New Mexico Health Sciences Center 2021T32GM144834 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Judy Lin Cannon, Bryce C Chackerian · 2022 to 2026
$2.7M
Lysosome‐Lipid Droplet Interactions in Fatty Acid MetabolismR35GM147419 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Jing Pu · 2022 to 2026
$1.9M
NCATS NIH HHS UL1 TR001449NCI NIH HHS P30 CA118100NIGMS NIH HHS P20 GM121176NIGMS NIH HHS R35 GM147419NIGMS NIH HHS T32 GM144834
6 · The paper itself

Abstract

Background & Aims: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) represent progressive stages of liver disease, with distinct metabolic and cellular alterations. This study investigates the progression from MASLD to MASH through metabolomics, lipidomics, and assessment of hormones. Methods: Male C57BL/6NTac mice were fed a high-fat diet for 16 weeks to induce MASLD and for 29 weeks to develop MASH. Aged-matched controls on a normal diet were used for comparison. Histology confirmed the progression of MASLD to MASH. We performed metabolomic and lipidomic profiling of liver, colon, and stool samples to identify metabolic and lipid alterations. Plasma enteroendocrine hormones and cytokines were quantified. Immunofluorescence was performed to assess enteroendocrine cells changes in the colon and the association of serotonin (5-HT) with fibronectin in the liver. Results: Metabolomic and lipidomic analysis revealed significant alterations at different stages of the disease. Specifically, cholic acid was increased across the liver, colon, and stool in both MASLD and MASH mice compared to controls. Compared to the control group, MASLD mice exhibited an increase in enteroendocrine hormones, GLP-1, GIP, and PYY, whereas no changes were observed in MASH mice. Comparing MASLD to MASH livers, we found hepatic 5-HT levels were increased in MASH mice compared to MASLD mice. The MASH liver also exhibited a colocalization between fibronectin and 5-HT, suggesting a potential role of 5-HT in liver fibrosis. Conclusions: Our study provides novel insights into the progressive metabolic and hormonal changes from MASLD to MASH. The increase in cholic acid and differential enteroendocrine hormone responses highlight the complex interactions between the gut and liver in metabolic liver diseases. These findings suggest that enteroendocrine hormones may play a role in the progression of MASLD to MASH as well as liver fibrosis, offering potential therapeutic avenues for targeting the gut-liver axis in metabolic liver diseases.

Indexed as

Enteroendocrine HormonesLipidomicsMASHMASLDMetabolomics

Identifiers

PMID41000700
PMCPMC12458355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.